In a recent prospective Chinese study, a bismuth compound was added to the legacy PPI-based triple therapy and concluded that the H. pylori eradication rate became >90%. Increased treatment duration was also essential. A therapeutic gain of 13% was achieved if the regimen was administered for 14 days instead of 7 days. Clarithromycin resistance can also overcome by the prolonged bismuth containing quadruple therapy (43).
展开▼
